Cerus Corporation (CERS) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Product Revenue: Q2 2026 product revenue reached $57.4 million, a 10% increase year-over-year. For the first half of 2026, product revenue totaled $111.1 million, up 16% from $95.7 million in H1 2025.

Gross Margin: Q2 gross margin was 51.4%, down from 55.2% in Q2 2025, attributed to currency fluctuations and inflationary pressures.

Net Loss: GAAP net loss improved to $2.9 million from $5.7 million in Q2 2025. Non-GAAP adjusted EBITDA was $3 million, marking the ninth consecutive quarter of positive adjusted EBITDA.

Cash Flow: Cash used in operations was $2.7 million, driven by increased inventory levels.

2Strategic Updates and Business Highlights

Growth Initiatives:

Worldwide product revenue growth driven by the U.S. IFC franchise and global core business.

Collaboration with Blood Centers of America (BCA) is enhancing market penetration and customer engagement.

Positive momentum in EMEA with the rollout of the INT200 device and a new contract with the French Blood Establishment.

Innovation:

Successful completion of the Notified Body Recertification Audit with zero nonconformities.

PMA submission for INT200 for platelets to the U.S. FDA; potential approval expected in H1 2027.

Ongoing clinical trials for INTERCEPT red blood cells, with top-line results from the Phase 3 RedeS trial anticipated in Q4 2026.

3Forward Guidance and Outlook

Revenue Guidance:

Full-year 2026 product revenue guidance raised to $229-$231 million (previously $227-$231 million).

IFC revenue guidance increased to $23-$25 million (previously $22-$24 million).

Growth Expectations: Anticipated year-over-year product revenue growth of 11%-12% and approximately 40%-50% growth for IFC.

4Bad News, Challenges, or Points of Concern

Gross Margin Pressure: Continued headwinds from inflation and currency exchange rates affecting gross margins, anticipated to remain in the low 50s for 2026.

Declining Government Contract Revenue: Revenue from government-related R&D expenses decreased to $5.9 million from $7.7 million in Q2 2025, primarily due to the completion of previous contracts.

Market Penetration: Despite growth, INTERCEPT products still have significant room for market penetration, particularly in the U.S. platelet market where one-third remains under-penetrated.

5Notable Q&A Insights

IFC Adoption: The adoption of IFC is not typically driven by individual hospital studies but rather through partnerships with blood centers like BCA, which accelerates the process.

Market Dynamics: The U.S. platelet market shows a bimodal distribution in penetration, with opportunities for growth primarily in BCA member blood centers.

International Expansion: Positive engagement in Asia-Pacific markets, particularly in China and Japan, with ongoing efforts to gather clinical data for regulatory submissions.

Clinical Validation: The contract with EFS in France serves as significant validation for INTERCEPT technology, enhancing credibility and potential for future contracts. Overall, Cerus Corporation demonstrated solid financial performance in Q2 2026, with strategic initiatives aimed at expanding market share and advancing product innovation, despite facing challenges related to gross margins and market penetration.